Dix says confidential discussions with multiple potential partners are being held for its NRF-2 activator programme which is focused on chronic obstructive pulmonary disease and pulmonary arterial hypertension as well as sickle cell disease.
C4X Discovery in advanced discussions to partner its 'world-leading' NRF-2 programme
Quick facts: C4X Discovery Holdings PLC
Price: 12.5 GBX
Market Cap: £13.55 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of C4X Discovery Holdings PLC named herein, including the promotion by the Company of C4X Discovery Holdings PLC in any Content on the Site, the...FOR OUR FULL DISCLAIMER CLICK HERE